Diabetes Mellitus, Type 2 study: Semaglutide vs Nicotine replacement
Official title Semaglutide for Smoking Cessation in Patients With Diabetes
ClinicalTrials.gov ID: NCT07059377
What this study is testing
What is Semaglutide?
An investigational once‑weekly injectable medicine being studied as a possible aid for smoking cessation in people with type 2 diabetes. It is designed to activate GLP‑1 receptors, which helps increase insulin secretion, lower blood sugar, and reduce appetite.
Also referred to as Ozempic, Wegovy.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study checks if it is possible to run a larger trial to see if semaglutide helps people stop smoking when used with nicotine patches or gum.
- Who it's for
- People with type 2 diabetes who currently smoke and want to quit.
- What's involved
- Participants will take semaglutide along with standard nicotine replacement therapy and attend study visits.
- Time commitment
- The source text does not specify the duration or number of visits.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults (18 years or older) with type 2 diabetes
- Currently residing in Ontario
- Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months
- Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.
- Have not used GLP-1 receptor agonists in the past six months.
You likely can't join if
- Pregnant or breastfeeding individuals
- Contraindication to NRT or GLP-1 RA.
- Current daily use of NRT or a GLP1 RA.
- Use of bupropion, cytisine, and varenicline within the last 7 days.
- Use of a DPP-IV inhibitor within the last 7 days.
- Initiation of a new diabetes medication within the last 3 months.
See the full eligibility criteria
- Adults (18 years or older) with type 2 diabetes
- Currently residing in Ontario
- Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months
- Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.
- Have not used GLP-1 receptor agonists in the past six months.
- Able to provide informed consent
- Pregnant or breastfeeding individuals
- Contraindication to NRT or GLP-1 RA.
- Current daily use of NRT or a GLP1 RA.
- Use of bupropion, cytisine, and varenicline within the last 7 days.
- Use of a DPP-IV inhibitor within the last 7 days.
- Initiation of a new diabetes medication within the last 3 months.
- As per the product monograph, participants with the following diagnoses or disorders will be excluded;
- Personal or family history of medullary thyroid cancer
- Personal or family history of Multiple Endocrine Neoplasia syndrome type 2
- Diabetic ketoacidosis
- Type I diabetes
- Acute pancreatitis or pancreatic cancer
- Acute, chronic or end-stage renal failure
- Tachyarrhythmias
- Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French).
- Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year).
The study team makes the final eligibility decision.
Where it is enrolling
- Ottawa, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Ottawa, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.